These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 18993152

  • 1. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Alrasadi K, Awan Z, Alwaili K, Ruel I, Hafiane A, Krimbou L, Genest J.
    Am J Cardiol; 2008 Nov 15; 102(10):1341-7. PubMed ID: 18993152
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Nov 15; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 15; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 4. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 15; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 5. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 15; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 6. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 15; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 7. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
    Penn R, Williams RX, Guha-Ray DK, Sawyers WG, Braun SL, Rains KT.
    Clin Ther; 2006 Jan 15; 28(1):45-54. PubMed ID: 16490579
    [Abstract] [Full Text] [Related]

  • 8. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.
    J Indian Med Assoc; 2006 Sep 15; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [Abstract] [Full Text] [Related]

  • 9. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 15; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 10. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
    Yeganeh B, Moshtaghi-Kashanian GR, Declercq V, Moghadasian MH.
    J Nutr Biochem; 2005 Apr 15; 16(4):222-8. PubMed ID: 15808326
    [Abstract] [Full Text] [Related]

  • 11. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Sang ZC, Wang F, Zhou Q, Li YH, Li YG, Wang HP, Chen SY.
    Chin Med J (Engl); 2009 Jul 20; 122(14):1615-20. PubMed ID: 19719960
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
    Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am J Cardiol; 2009 Feb 15; 103(4):515-22. PubMed ID: 19195513
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
    Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, McTaggart F, Schaefer EJ.
    Am J Cardiol; 2007 Mar 01; 99(5):681-5. PubMed ID: 17317371
    [Abstract] [Full Text] [Related]

  • 14. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ, Zwang L, Huisman MV, Banga JD, Sluiter WJ, Dallinga-Thie GM, Dullaart RP.
    Expert Opin Ther Targets; 2009 Jul 01; 13(7):743-51. PubMed ID: 19505224
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
    Ferrer-García JC, Sanchez-Ballester E, Albalat-Galera R, Berzosa-Sanchez M, Herrera-Ballester A.
    J Cardiovasc Pharmacol Ther; 2008 Sep 01; 13(3):183-8. PubMed ID: 18635754
    [Abstract] [Full Text] [Related]

  • 16. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.
    Am J Cardiol; 2008 Feb 15; 101(4):486-9. PubMed ID: 18312763
    [Abstract] [Full Text] [Related]

  • 17. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C, Athyros V, Gaw A, ACTFAST-2 investigators and Steering Committee members.
    Curr Med Res Opin; 2007 Aug 15; 23(8):1945-56. PubMed ID: 17626713
    [Abstract] [Full Text] [Related]

  • 18. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC, Van Tol A, Dallinga-Thie GM, Liem A, Dunselman PH, Van der Bom JG, Jukema JW.
    Curr Med Res Opin; 2007 Sep 15; 23(9):2235-40. PubMed ID: 17692153
    [Abstract] [Full Text] [Related]

  • 19. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV, Yegorova YV.
    Kardiol Pol; 2006 Jan 15; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [Abstract] [Full Text] [Related]

  • 20. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C, Lilli S, Gentile A, Patti L, Di Marino L, Cipriano P, Riccardi G, Rivellese AA.
    Eur J Clin Invest; 2006 Aug 15; 36(8):560-5. PubMed ID: 16893378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.